Appendix B: Sources of Evidence

Appendix B: Sources of Evidence

i) The following documentation and opinion was made available to the Committee:

a) Assessment Report The effectiveness of inhaler devices for young children with asthma; Prepared by Payne N & Beard S, Trent Institute for Health Services Research, School of Health & Related Research, University of Sheffield;Wright, Brocklebank,D & Ram F, Bradford Hospitals NHS Trust; Taylor RS, National Institute for Clinical Excellence. March 2000.

b) Manufacturer/Sponsor submissions:

i. AstraZeneca

ii. Boehringer Inglheim Ltd.

iii. Aventis Pharma (formerly Rhône-Poulenc Rorer)

iv. Boehringer Inglheim Ltd.

v. Glaxo Wellcome

vi. 3M Health Care Ltd.

vii. Norton Healthcare

viii.Yamanouchi Pharma Ltd.

c) Professional/specialist group, patient/carer group and trade association submissions;

i. Association of British Health-Care Industries

ii. British Medical Association

iii. British Thoracic Society

iv. National Asthma Campaign

v. Royal College of Nursing

vi. Royal College of Paediatrics & Child Health

vii. Royal College of Physicians

ii) The following experts were invited to make submissions to the Committee:

a) Dr Andrew Bush, Reader in Paediatric Respirology & Honorary Consultant Paediatric Chest Physician, Royal Brompton Hospital, London.

b) Dr C O'Callaghan, Senior Lecturer & Consultant Paediatrician,University of Leicester & Leicester Royal Infirmary Children's Hospital.